Want to see HK:1875 full AI Analyst Report?
Top Page
TOT BIOPHARM International Co. Ltd.
(1875)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$3.00
▲(20.00% Upside)
Action:Reiterated
Date:06/02/26
The score is weighed down primarily by weak financial performance (2025 revenue decline, return to losses, and persistently negative free cash flow) and bearish technical signals (price below key moving averages with negative MACD). Valuation provides limited support given the negative P/E and no dividend yield data.
Positive Factors
Diversified revenue streams (product sales + CDMO)
Having both oncology product sales and CDMO/CMO service revenue creates durable revenue diversification. CDMO contracts tend to be multi-period and service-driven, providing steadier cash inflows and reducing reliance on single-product commercialization outcomes over a 2–6 month horizon.
Negative Factors
Sharp 2025 revenue decline and return to losses
A ~32% revenue drop and swing back to losses represent structural execution or demand issues that reduce internal funding for pipeline programs and commercial expansion. This weakens self-funding capacity and heightens refinancing and operational risk over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams (product sales + CDMO)
Having both oncology product sales and CDMO/CMO service revenue creates durable revenue diversification. CDMO contracts tend to be multi-period and service-driven, providing steadier cash inflows and reducing reliance on single-product commercialization outcomes over a 2–6 month horizon.
Read all positive factors
TOT BIOPHARM International Co. Ltd. (1875) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.53B
Dividend YieldN/A
Average Volume (3M)240.51K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue Growth-32.12%
EPS Growth-374.47%
CountryHK
Employees611
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding772,787,900
10 Day Avg. Volume141,880
30 Day Avg. Volume240,506
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.60
Price to Sales (P/S)2.18
P/FCF Ratio-60.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.40Price Target Upside76.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$566.06M
TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model
Company Description
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key pro...
How the Company Makes Money
The company makes money primarily through (1) sales of pharmaceutical products, where revenue is generated from distributing and selling its oncology-focused medicines (including specialty/complex injectables and related anti-cancer therapeutics) ...
TOT BIOPHARM International Co. Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
62
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 747.64M | 1.10B | 780.63M | 442.18M | 76.33M |
| Gross Profit | 388.98M | 782.43M | 573.99M | 370.62M | 27.47M |
| EBITDA | -6.44M | 84.96M | 10.45M | -5.41M | -224.51M |
| Net Income | -100.37M | 34.76M | -37.76M | -49.92M | -261.22M |
Balance Sheet | |||||
| Total Assets | 1.26B | 1.51B | 1.43B | 1.26B | 710.26M |
| Cash, Cash Equivalents and Short-Term Investments | 328.47M | 381.26M | 351.60M | 517.63M | 155.38M |
| Total Debt | 383.72M | 395.47M | 345.65M | 289.53M | 208.56M |
| Total Liabilities | 633.75M | 779.12M | 739.41M | 546.59M | 375.17M |
| Stockholders Equity | 626.08M | 729.65M | 686.69M | 713.88M | 335.09M |
Cash Flow | |||||
| Free Cash Flow | -26.93M | -7.17M | -146.77M | -180.19M | -290.45M |
| Operating Cash Flow | 16.14M | 116.40M | 56.43M | 59.93M | -175.14M |
| Investing Cash Flow | -43.07M | -122.50M | -164.10M | -282.76M | -108.39M |
| Financing Cash Flow | -25.66M | 34.18M | 38.23M | 481.24M | 212.08M |
TOT BIOPHARM International Co. Ltd. Technical Analysis
Negative
2.50
Price Trends
4.12
Negative
4.32
Negative
3.32
Negative
Market Momentum
-0.25
Negative
36.48
Neutral
39.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Negative. The current price of 2.5 is below the 20-day moving average (MA) of 3.43, below the 50-day MA of 4.12, and below the 200-day MA of 3.32, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 36.48 is Neutral, neither overbought nor oversold. The STOCH value of 39.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1875.
TOT BIOPHARM International Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$35.11B | 36.63 | 23.99% | ― | 16.65% | 0.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$7.02B | 23.29 | 24.17% | ― | 154.21% | ― | |
46 Neutral | HK$6.77B | -55.90 | -6.26% | ― | -11.65% | -169.40% | |
45 Neutral | HK$2.53B | -21.10 | -14.78% | ― | -32.12% | -374.47% | |
44 Neutral | HK$8.59B | -68.31 | -11.21% | ― | 219.26% | 87.63% | |
41 Neutral | HK$34.22B | -52.03 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1875
TOT BIOPHARM International Co. Ltd.
3.28
1.37
71.73%
HK:9966
Alphamab Oncology
6.95
0.85
13.93%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
16.65
-4.10
-19.76%
HK:2157
Lepu Biopharma Co. Ltd. Class H
3.89
-1.64
-29.66%
HK:2171
CARsgen Therapeutics Holdings Ltd.
14.26
-8.84
-38.27%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
64.40
12.10
23.14%
TOT BIOPHARM International Co. Ltd. Corporate Events
BioDlink reshapes company secretarial team under HKEX waiver
Jun 26, 2026
BioDlink International Company Limited has reshuffled its corporate secretarial team, with joint company secretary Mr. Chen Yifan resigning effective 26 June 2026 and Ms. Fang Yuan stepping in as his replacement alongside existing joint company se...
BioDlink Wins Unanimous Shareholder Backing for Board Mandates at AGM
Jun 26, 2026
BioDlink International Company Limited reported that all resolutions at its 26 June 2026 annual general meeting were passed by poll with 100% approval from votes cast. Shareholders endorsed the 2025 audited financial statements, re‑elected a...
BioDlink Wins RMB19 Million Monoclonal Antibody Manufacturing Mandate from WuXi Biologics
Jun 16, 2026
BioDlink International has signed a process development and manufacturing services agreement with WuXi Biologics under which it will supply ten batches of monoclonal antibody intermediates by the end of 2026 for a total fee of RMB19 million. The d...
BioDlink Shareholders Approve CDMO Master Agreement With WuXi XDC
Jun 11, 2026
Shareholders of BioDlink International Company Limited have approved a CDMO master services agreement with WuXi XDC Cayman Inc. at an extraordinary general meeting held on 11 June 2026. The resolution, which also endorsed annual caps for the agree...
BioDlink to Replace PwC with Deloitte as Auditor in Governance-Driven Shift
Jun 4, 2026
BioDlink International Company Limited has announced that PricewaterhouseCoopers will retire as its auditor at the conclusion of the upcoming annual general meeting, after serving since the company’s 2019 listing. The board emphasized that P...
BioDlink Calls 2026 AGM to Approve Accounts, Board Changes and Share Issue Mandate
Jun 4, 2026
BioDlink International Company Limited has convened a hybrid annual general meeting for 26 June 2026, combining a physical venue in Wuxi, Jiangsu, with an online option for shareholders. The agenda includes receiving and approving the audited cons...
BioDlink sets pricing controls and payment terms for continuing connected deals
Jun 3, 2026
BioDlink International Company Limited has issued a supplemental announcement detailing how it will manage continuing connected transactions under its agreements with WuXi XDC and other related parties. The company outlines internal controls to en...
BioDlink Flags No Undisclosed Issues Amid Share Volatility and Deepens WuXi XDC CDMO Ties
Jun 2, 2026
BioDlink International Company Limited said it had observed unusual movements in its share price and trading volume but, after an internal review, the board stated it was unaware of any undisclosed material adverse developments or inside informati...
BioDlink Sets Long-Term Connected Deals With WuXi XDC, Triggers Shareholder Oversight
May 26, 2026
BioDlink International has entered into a series of continuing connected transaction agreements with controlling shareholder WuXi XDC, effective immediately through 31 December 2028. These agreements cover CDMO master services, manufacturing, raw ...
BioDlink Calls Hybrid EGM to Approve WuXi XDC CDMO Master Services Deal
May 26, 2026
BioDlink International Company Limited has called a hybrid extraordinary general meeting for 11 June 2026 in Suzhou and online to seek shareholder approval for a CDMO Master Services Agreement with WuXi XDC Cayman Inc. The proposed resolution also...
BioDlink Sets Out Board Composition and Key Committee Roles
Apr 28, 2026
BioDlink International Company Limited has announced the current composition of its board of directors and clarified the roles and functions of each member. The company has also detailed the makeup of its four key board committees—Audit and ...
BioDlink Overhauls Board After WuXi XDC Takes Control
Apr 28, 2026
BioDlink International Company Limited announced a sweeping board overhaul following a change in control after voluntary general cash offers resulted in WuXi XDC Cayman Inc. becoming its controlling shareholder. With effect from 29 April 2026, the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.